Please login to the form below

Not currently logged in
Email:
Password:

EMA recommends Lilly’s erectile dysfunction drug for enlarged prostate

Cialis would be first drug available in Europe for both ED and BPH

Eli Lilly's erectile dysfunction (ED) drug Cialis has been recommended in the EU for the treatment of men with an enlarged prostate.

The European Medicines Agency (EMA) has said the drug should be available to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition that has been shown to occur often in men with ED.

If approved, Cialis (tadalafil) would be the first drug available in Europe to treat both conditions, with Lilly suggesting a potential market of millions of men throughout the region.

The two indications gives Cialis a potential advantage over drugs approved for just one or the other, including Pfizer's Viagra (sildenafil) for ED and Abbott's Hytrin (terazosin HCl) for BPH.

Cialis is already available in the US to treat both conditions having received approval for BPH in October 2011. This helped towards a slight boost in US sales of Cialis of 3 per cent during the second quarter of 2012, reaching $186.6m.

Other countries where it is also approved for BPH include Canada, Mexico, Brazil, South Korea, Russia, Panama and Argentina.

Lilly also warned that Cialis should not be use by people already taking nitrate medicines, such as isosorbide dinitrate or isosorbide mononitrate.

These drugs are often prescribed for chest pain and can lead to an unsafe drop in blood pressure when combined with a PDE5 inhibitor like Cialis.

A similar warning was given for recreational drugs known as 'poppers', which include amyl and butyl nitrite.

25th September 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

How to get management buy-in for content marketing
Pharma content marketing is still fairly new in the scheme of things for the pharma industry. In the conservative and traditional pharma industry that’s fraught with regulations, getting management buy-in...
Paywatch and the market access waters
Understanding and responding to payers’ needs has become priority number one for pharma as it battles the choppy seas of the global health economy...
EY Life Sciences Sector Update
Asia-Pacific and Japan...

Infographics